Home / Market News / $TEVA
benzinga Corporate Catalyst Impact 85/100 ● positive

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

Oct 9, 2026, 4:28 PM UTC · Primary ticker $TEVA

Teva Pharmaceutical Industries Ltd. announced FDA approval for Weltruza, a new once-monthly subcutaneous injectable for schizophrenia. This approval is a significant positive for Teva, addressing a critical adherence issue in schizophrenia treatment and supporting the company's 'Pivot to Growth' strategy.

Teva Pharmaceutical Industries Ltd. received FDA approval for Weltruza, a long-acting injectable olanzapine for schizophrenia. This is a significant development as it addresses a major unmet need in schizophrenia treatment by improving patient adherence, which is a common problem with daily oral medications. The approval is a strong positive catalyst for Teva, reinforcing its 'Pivot to Growth' strategy and potentially opening up a substantial market given the 2.1 million Americans diagnosed with schizophrenia. For traders, this presents a clear buying opportunity for TEVA in the short to medium term, as the drug is set to launch in the U.S. in the coming weeks and has European expansion plans. The proprietary SteadyTeq technology developed by Medincell also benefits that company.

$TEVA positive FDA approval of new drug
$MDCL positive Proprietary technology used in approved drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.